RxDoctor Payments Data

Craig Brett, MD

Cardiovascular Disease · Portland, MENPI 1841270535

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.2% of the total across 19 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by Johnson & Johnson at 29.2% of the total. Reporting peaked in 2019 at $192 and has fallen 89.4% since, to $20 in 2023.

$294in general payments, 2019–2025

Across 19 payments — averaging $15.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$86
  • Novartis$38
  • Sanofi-aventis U.S. LLC$33
  • Pfizer$32
  • Preventice Services, LLC$31
  • AstraZeneca$29
  • plus $44 from 3 others

What the payments were for

  • Food & beverage$29299%
  • Education$21%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$294 in reported general payments places this provider in the 60th percentile of 99 cardiovascular disease providers in Maine.

See all cardiovascular disease providers in Maine

Medicare billing

Part B allowed, 2024
$67,425
Medicare patients
827
Services billed
1,624

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban426$549,755
XareltoRivaroxaban236$275,155
Repatha SureclickEvolocumab243$187,536
EntrestoSacubitril/Valsartan43$54,813
Praluent PenAlirocumab45$39,170
NexlizetBempedoic Acid/Ezetimibe22$15,889
Repatha SyringeEvolocumab23$12,627
Rosuvastatin Calcium367$9,972
NexletolBempedoic Acid13$8,179
Metoprolol Succinate338$5,276
Diltiazem 24hr Er (Cd)Diltiazem Hcl63$3,609
Flecainide Acetate59$2,964
Atorvastatin Calcium188$2,425
Warfarin Sodium256$1,976
Ranolazine ErRanolazine19$1,923

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$32$549,755426 claims
Johnson & JohnsonXarelto$86$275,155236 claims
NovartisEntresto$38$54,81343 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 99 cardiovascular disease providers in Maine.

Other cardiovascular disease in Portland

See the full list for Maine

Where these figures come from

Is this you, or does something look wrong? →